LYTIR

Company · HIMS

Hims & Hers Health, Inc.

Nasdaq's symbol directory lists HIMS on the New York Stock Exchange as “Hims & Hers Health, Inc. Class A Common Stock”.

In the 12 months to Nov 19, 2026: insiders sold on 26 occasions ($10.3M); 12 planned-sale notices; 5 filings by holders of 5% or more; 1 congressional trade disclosure; 3 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $10.3M in total.Jun: Insider sales $5.2MJul: Insider sales $491KAug: Insider sales $1.6MSep: Insider sales $2.2MOct: Insider sales $256KNov: Insider sales $571KDecJanFebMarAprMayJunJulAugSepOctNov$5.2M
Insider purchases above the line: $0Insider sales below: $10.3M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Oluyemi Okupe, Chief Financial Officer sold on 10 days all under a 10b5-1 plan latest Nov 17, 2026 sold $4.8M
  2. Soleil Boughton, Chief Legal Officer sold on 7 days all under a 10b5-1 plan latest Nov 17, 2026 sold $1.3M
  3. Mohamed Elshenawy, CTO sold on 2 days all under a 10b5-1 plan latest Sep 15, 2026 sold $1.2M
  4. Autor Deborah M., Chief Policy Officer sold on 2 days all under a 10b5-1 plan latest Nov 17, 2026 sold $909K
  5. Chi Michael, Chief Operating Officer sold on 2 days all under a 10b5-1 plan latest Sep 15, 2026 sold $840K
  6. Carroll Patrick Harrison, Chief Medical Officer sold on 1 day all under a 10b5-1 plan latest Jun 18, 2026 sold $830K
  7. Becklund Irene, PAO sold on 2 days all under a 10b5-1 plan latest Jun 17, 2026 sold $371K
Every trade (26)
  1. SELLAutor Deborah M., Chief Policy Officer sold Nov 17, 2026 23,828 shares 10b5-1 plan (scheduled) filing $442K
  2. SELLOluyemi Okupe, Chief Financial Officer sold Nov 17, 2026 3,518 shares 10b5-1 plan (scheduled) filing $65K
  3. SELLSoleil Boughton, Chief Legal Officer sold Nov 17, 2026 3,458 shares 10b5-1 plan (scheduled) filing $64K
  4. SELLSoleil Boughton, Chief Legal Officer sold Oct 28, 2026 3,462 shares 10b5-1 plan (scheduled) filing $96K
  5. SELLSoleil Boughton, Chief Legal Officer sold Oct 14, 2026 3,461 shares 10b5-1 plan (scheduled) filing $101K
  6. SELLOluyemi Okupe, Chief Financial Officer sold Oct 1, 2026 2,000 shares 10b5-1 plan (scheduled) filing $59K
  7. SELLSoleil Boughton, Chief Legal Officer sold Sep 30, 2026 3,461 shares 10b5-1 plan (scheduled) filing $101K
  8. SELLOluyemi Okupe, Chief Financial Officer sold Sep 22, 2026 29,277 shares 10b5-1 plan (scheduled) filing $877K
  9. SELLOluyemi Okupe, Chief Financial Officer sold Sep 17, 2026 12,313 shares 10b5-1 plan (scheduled) filing $355K
  10. SELLSoleil Boughton, Chief Legal Officer sold Sep 16, 2026 6,236 shares 10b5-1 plan (scheduled) filing $174K
  11. SELLChi Michael, Chief Operating Officer sold Sep 15, 2026 14,027 shares 10b5-1 plan (scheduled) filing $398K
  12. SELLMohamed Elshenawy, CTO sold Sep 15, 2026 7,954 shares 10b5-1 plan (scheduled) filing $226K
  13. SELLSoleil Boughton, Chief Legal Officer sold Sep 2, 2026 3,458 shares 10b5-1 plan (scheduled) filing $98K
  14. SELLSoleil Boughton, Chief Legal Officer sold Aug 19, 2026 25,111 shares 10b5-1 plan (scheduled) filing $692K
  15. SELLOluyemi Okupe, Chief Financial Officer sold Aug 19, 2026 4,938 shares 10b5-1 plan (scheduled) filing $148K
  16. SELLAutor Deborah M., Chief Policy Officer sold Aug 18, 2026 16,773 shares 10b5-1 plan (scheduled) filing $467K
  17. SELLOluyemi Okupe, Chief Financial Officer sold Aug 17, 2026 9,388 shares 10b5-1 plan (scheduled) filing $262K
  18. SELLOluyemi Okupe, Chief Financial Officer sold Jul 17, 2026 7,163 shares 10b5-1 plan (scheduled) filing $229K
  19. SELLOluyemi Okupe, Chief Financial Officer sold Jul 6, 2026 7,163 shares 10b5-1 plan (scheduled) filing $261K
  20. SELLOluyemi Okupe, Chief Financial Officer sold Jun 22, 2026 18,197 shares 10b5-1 plan (scheduled) filing $619K
  21. SELLOluyemi Okupe, Chief Financial Officer sold Jun 18, 2026 55,383 shares 10b5-1 plan (scheduled) filing $1.9M
  22. SELLCarroll Patrick Harrison, Chief Medical Officer sold Jun 18, 2026 23,726 shares 10b5-1 plan (scheduled) filing $830K
  23. SELLMohamed Elshenawy, CTO sold Jun 17, 2026 30,040 shares 10b5-1 plan (scheduled) filing $946K
  24. SELLChi Michael, Chief Operating Officer sold Jun 17, 2026 14,027 shares 10b5-1 plan (scheduled) filing $442K
  25. SELLBecklund Irene, PAO sold Jun 17, 2026 4,490 shares 10b5-1 plan (scheduled) filing $141K
  26. SELLBecklund Irene, PAO sold Jun 16, 2026 7,573 shares 10b5-1 plan (scheduled) filing $229K

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. Autor Deborah M. filed Nov 17, 2026 Officer 23,828 shares planned sale date 11/17/2026 filing $442K
  2. Okupe Oluyemi filed Nov 17, 2026 Officer 3,518 shares planned sale date 11/17/2026 filing $65K
  3. Boughton Soleil filed Nov 17, 2026 Officer 3,458 shares planned sale date 11/17/2026 filing $64K
  4. Boughton Soleil filed Oct 28, 2026 Officer 3,462 shares planned sale date 10/28/2026 filing $96K
  5. Boughton Soleil filed Oct 14, 2026 Officer 3,461 shares planned sale date 10/14/2026 filing $101K
  6. Okupe Oluyemi filed Oct 1, 2026 Officer 2,000 shares planned sale date 10/01/2026 filing $59K
  7. Boughton Soleil filed Sep 30, 2026 Officer 3,461 shares planned sale date 09/30/2026 filing $101K
  8. Okupe Oluyemi filed Sep 22, 2026 Officer 29,277 shares planned sale date 09/22/2026 filing $877K
  9. Okupe Oluyemi filed Sep 17, 2026 Officer 12,313 shares planned sale date 09/17/2026 filing $355K
  10. Boughton Soleil filed Sep 16, 2026 Officer 6,236 shares planned sale date 09/16/2026 filing $174K
  11. Chi Michael filed Sep 15, 2026 Officer 14,027 shares planned sale date 09/15/2026 filing $398K
  12. Elshenawy Mohamed filed Sep 15, 2026 Officer 7,954 shares planned sale date 09/15/2026 filing $226K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. G1 Execution Services, LLC filed Nov 16, 2026 Schedule 13G/A passive filing 4.8%
  2. Vanguard Capital Management filed Oct 30, 2026 Schedule 13G/A passive 11,190,115 shares filing 4.97%
  3. Andrew Dudum filed Aug 31, 2026 Schedule 13D/A may seek influence 22,610,002 shares filing 9.4%
  4. Vanguard Capital Management filed Jul 31, 2026 Schedule 13G passive 11,188,807 shares filing 5.01%
  5. BlackRock, Inc. filed Jul 28, 2026 Schedule 13G/A passive 26,496,218 shares filing 11.9%

Congress · STOCK Act

The Althing

Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.

  1. Tony Wied (R-WI08): Purchase Feb 3, 2026 reported Mar 9, 2026 one of 25 trades the member reported that day House owner: joint $50,001 - $100,000

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Departure or appointment of directors or officers filing Nov 9, 2026
  2. Results of operations and financial condition; Other events filing Nov 9, 2026
  3. Departure or appointment of directors or officers filing Oct 7, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.